Maritide vs Tirzepatide: What Does the Evidence Actually Show?

What exactly is maritide, and how does it differ from tirzepatide mechanically?

Tirzepatide activates two gut-hormone receptors simultaneously, GLP-1 and GIP. That dual action sets it apart from earlier injectable treatments, and it is the basis for the weight-loss results seen in the SURMOUNT clinical programme. Maritide targets a different pair: GLP-1 and glucagon receptors. The glucagon pathway raises metabolic rate, which in theory could add a complementary mechanism for burning energy rather than primarily reducing appetite. Early researchers are interested in whether that combination might offer advantages for people with fatty liver disease or metabolic dysfunction alongside obesity.

Practically speaking, both are injectable medicines studied for weight management in adults, but the similarities largely stop there. Tirzepatide is made by Eli Lilly, has completed large phase-3 trials, and was approved by the MHRA. Maritide, developed by Amgen, is still in phase-2 research. Trial data published so far comes from relatively small cohorts over shorter periods. A direct, like-for-like comparison in the same population, over the same timeframe, does not yet exist, which means any headline figures you might see comparing the two should be read very carefully. The NHS medicines information for tirzepatide covers how the approved medicine works and what patients can expect.

For people exploring how tirzepatide fits into the broader GLP-1 medicine landscape, understanding these receptor differences is useful context, even if it does not change what is currently available on prescription.

What does the evidence show for each medicine's weight-loss results?

Tirzepatide's phase-3 SURMOUNT-1 trial enrolled 2,539 adults with obesity and no diabetes. At the highest dose studied, average body-weight reduction reached approximately 20–21% over 72 weeks, with some analyses reporting up to around 22.5%. Those are the results that informed NICE's recommendation, published in December 2024 (NICE technology appraisal TA1026), that tirzepatide be made available for adults with a BMI of 35 or above and at least one weight-related condition. The evidence base is substantial.

Maritide's published data comes from earlier-stage work. Phase-2 results reported roughly 18–19% average weight reduction at the higher doses studied over about 52 weeks, promising figures, but drawn from a much smaller group, over a shorter follow-up, without the regulatory scrutiny a phase-3 programme brings. Phase-3 trials are underway, but results are not yet available, and no regulatory submission has been made to the MHRA or any major medicines agency at the time of writing.

The table below summarises the key facts as they stand.

Those who want to explore how tirzepatide performed against another approved injectable can read about the relationship between tirzepatide and Mounjaro) the short version is that they are the same molecule, different name.

Can you get maritide in the UK, and what are the alternatives if you cannot wait?

Maritide is not available as a prescription medicine anywhere in the world at present. It cannot be obtained through a UK pharmacy, whether NHS or private, because it has not completed the trials required for regulatory approval and no licence has been granted. Participating in a clinical trial is the only legitimate route to maritide right now, and eligibility for those trials is highly selective.

That leaves tirzepatide (Mounjaro) and semaglutide (Wegovy) as the two injectable weight-loss medicines licensed in the UK for adults who meet the clinical criteria. For people researching newer pipeline treatments, it can be genuinely frustrating to find that the options you read about most excitedly are still years from a prescription pad. That frustration is understandable. The honest position, though, is that licensing exists for good reason: it is the process that confirms a medicine is both effective and safe for real-world use, not just in early studies.

If you are trying to decide between what is actually available now, our page on retatrutide versus tirzepatide covers another pipeline medicine in the same pipeline-versus-licensed frame. For a broader look at the treatment options we offer, the weight-loss treatment overview is a good place to start. You can also read more about how our clinical team approaches these decisions. Anyone considering tirzepatide can find full details on our Mounjaro information page.

Which medicine is right for you, and how is that decision made?

Comparing two medicines on paper only takes you so far. The medicines you can actually access, your personal health history, current medications, BMI, and weight-related conditions all shape which treatment (if any) a prescriber would consider appropriate. Tirzepatide is not suitable for everyone: there are contraindications, interaction considerations and situations where a different approach makes more sense.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber who considers the full picture before any prescription is issued. There is no algorithm making the call. If you are unsure whether tirzepatide is right for you, or you want to understand how it compares to other licensed options, our prescribers work through exactly those questions with you.

For context on how tirzepatide sits alongside another pipeline candidate, the comparison of retatrutide and tirzepatide follows a similar structure. Those curious about whether the branded and generic names refer to the same thing can also find that answered in our guide to tirzepatide and Manjaro, which explains the relationship between the two. Those curious about the broader GLP-1 class can explore our frequently asked questions. Which treatment suits you is a clinical decision our prescribers make with you, based on your individual assessment, not a ranking on a comparison chart.